The global market for Kidney Fibrosis Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Kidney Fibrosis Drugs by region & country, by Type, and by Application.

The Kidney Fibrosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Drugs.

Market Segmentation

Scope of Kidney Fibrosis Drugs - Market Report

Report Metric	Details
Report Name	Kidney Fibrosis Drugs - Market
CAGR	5%
Segment by Type:	Angiotensin Converting Enzyme (ACE) Inhibitors Pirfenidone Renin Inhibitors Angiotensin II Receptor Blockers (ARBs) Vasopeptidase Inhibitors
Segment by Application	Chronic Kidney Diseases Kidney Cancer Treatment Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck and Co, Galectin Therapeutics, Pfizer Inc, InterMune Inc, La Jolla Pharmaceutical Company, BioLine Rx, F. Hoffman-La Roche, ProMetic Life-Sciences Inc, Genzyme Corporation
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Kidney Fibrosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Kidney Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Kidney Fibrosis Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Kidney Fibrosis Drugs - Market report?

Ans: The main players in the Kidney Fibrosis Drugs - Market are Merck and Co, Galectin Therapeutics, Pfizer Inc, InterMune Inc, La Jolla Pharmaceutical Company, BioLine Rx, F. Hoffman-La Roche, ProMetic Life-Sciences Inc, Genzyme Corporation

What are the Application segmentation covered in the Kidney Fibrosis Drugs - Market report?

Ans: The Applications covered in the Kidney Fibrosis Drugs - Market report are Chronic Kidney Diseases, Kidney Cancer Treatment, Others

What are the Type segmentation covered in the Kidney Fibrosis Drugs - Market report?

Ans: The Types covered in the Kidney Fibrosis Drugs - Market report are Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors

1 Market Overview

1.1 Kidney Fibrosis Drugs Product Introduction

1.2 Global Kidney Fibrosis Drugs Market Size Forecast

1.2.1 Global Kidney Fibrosis Drugs Sales Value (2019-2030)

1.2.2 Global Kidney Fibrosis Drugs Sales Volume (2019-2030)

1.2.3 Global Kidney Fibrosis Drugs Sales Price (2019-2030)

1.3 Kidney Fibrosis Drugs Market Trends & Drivers

1.3.1 Kidney Fibrosis Drugs Industry Trends

1.3.2 Kidney Fibrosis Drugs Market Drivers & Opportunity

1.3.3 Kidney Fibrosis Drugs Market Challenges

1.3.4 Kidney Fibrosis Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Kidney Fibrosis Drugs Players Revenue Ranking (2023)

2.2 Global Kidney Fibrosis Drugs Revenue by Company (2019-2024)

2.3 Global Kidney Fibrosis Drugs Players Sales Volume Ranking (2023)

2.4 Global Kidney Fibrosis Drugs Sales Volume by Company Players (2019-2024)

2.5 Global Kidney Fibrosis Drugs Average Price by Company (2019-2024)

2.6 Key Manufacturers Kidney Fibrosis Drugs Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Kidney Fibrosis Drugs Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Kidney Fibrosis Drugs

2.9 Kidney Fibrosis Drugs Market Competitive Analysis

2.9.1 Kidney Fibrosis Drugs Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Kidney Fibrosis Drugs Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Drugs as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors

3.1.2 Pirfenidone

3.1.3 Renin Inhibitors

3.1.4 Angiotensin II Receptor Blockers (ARBs)

3.1.5 Vasopeptidase Inhibitors

3.2 Global Kidney Fibrosis Drugs Sales Value by Type

3.2.1 Global Kidney Fibrosis Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Kidney Fibrosis Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Kidney Fibrosis Drugs Sales Value, by Type (%) (2019-2030)

3.3 Global Kidney Fibrosis Drugs Sales Volume by Type

3.3.1 Global Kidney Fibrosis Drugs Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Kidney Fibrosis Drugs Sales Volume, by Type (2019-2030)

3.3.3 Global Kidney Fibrosis Drugs Sales Volume, by Type (%) (2019-2030)

3.4 Global Kidney Fibrosis Drugs Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Chronic Kidney Diseases

4.1.2 Kidney Cancer Treatment

4.1.3 Others

4.2 Global Kidney Fibrosis Drugs Sales Value by Application

4.2.1 Global Kidney Fibrosis Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Kidney Fibrosis Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Kidney Fibrosis Drugs Sales Value, by Application (%) (2019-2030)

4.3 Global Kidney Fibrosis Drugs Sales Volume by Application

4.3.1 Global Kidney Fibrosis Drugs Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Kidney Fibrosis Drugs Sales Volume, by Application (2019-2030)

4.3.3 Global Kidney Fibrosis Drugs Sales Volume, by Application (%) (2019-2030)

4.4 Global Kidney Fibrosis Drugs Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Kidney Fibrosis Drugs Sales Value by Region

5.1.1 Global Kidney Fibrosis Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Kidney Fibrosis Drugs Sales Value by Region (2019-2024)

5.1.3 Global Kidney Fibrosis Drugs Sales Value by Region (2025-2030)

5.1.4 Global Kidney Fibrosis Drugs Sales Value by Region (%), (2019-2030)

5.2 Global Kidney Fibrosis Drugs Sales Volume by Region

5.2.1 Global Kidney Fibrosis Drugs Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Kidney Fibrosis Drugs Sales Volume by Region (2019-2024)

5.2.3 Global Kidney Fibrosis Drugs Sales Volume by Region (2025-2030)

5.2.4 Global Kidney Fibrosis Drugs Sales Volume by Region (%), (2019-2030)

5.3 Global Kidney Fibrosis Drugs Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Kidney Fibrosis Drugs Sales Value, 2019-2030

5.4.2 North America Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Kidney Fibrosis Drugs Sales Value, 2019-2030

5.5.2 Europe Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Kidney Fibrosis Drugs Sales Value, 2019-2030

5.6.2 Asia Pacific Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Kidney Fibrosis Drugs Sales Value, 2019-2030

5.7.2 South America Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Kidney Fibrosis Drugs Sales Value, 2019-2030

5.8.2 Middle East & Africa Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Kidney Fibrosis Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Kidney Fibrosis Drugs Sales Value

6.2.1 Key Countries/Regions Kidney Fibrosis Drugs Sales Value, 2019-2030

6.2.2 Key Countries/Regions Kidney Fibrosis Drugs Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Kidney Fibrosis Drugs Sales Value, 2019-2030

6.3.2 United States Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Kidney Fibrosis Drugs Sales Value, 2019-2030

6.4.2 Europe Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Kidney Fibrosis Drugs Sales Value, 2019-2030

6.5.2 China Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Kidney Fibrosis Drugs Sales Value, 2019-2030

6.6.2 Japan Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Kidney Fibrosis Drugs Sales Value, 2019-2030

6.7.2 South Korea Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Kidney Fibrosis Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Kidney Fibrosis Drugs Sales Value, 2019-2030

6.9.2 India Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Kidney Fibrosis Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Merck and Co

7.1.1 Merck and Co Company Information

7.1.2 Merck and Co Introduction and Business Overview

7.1.3 Merck and Co Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Merck and Co Kidney Fibrosis Drugs Product Offerings

7.1.5 Merck and Co Recent Development

7.2 Galectin Therapeutics

7.2.1 Galectin Therapeutics Company Information

7.2.2 Galectin Therapeutics Introduction and Business Overview

7.2.3 Galectin Therapeutics Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Galectin Therapeutics Kidney Fibrosis Drugs Product Offerings

7.2.5 Galectin Therapeutics Recent Development

7.3 Pfizer Inc

7.3.1 Pfizer Inc Company Information

7.3.2 Pfizer Inc Introduction and Business Overview

7.3.3 Pfizer Inc Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Pfizer Inc Kidney Fibrosis Drugs Product Offerings

7.3.5 Pfizer Inc Recent Development

7.4 InterMune Inc

7.4.1 InterMune Inc Company Information

7.4.2 InterMune Inc Introduction and Business Overview

7.4.3 InterMune Inc Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.4.4 InterMune Inc Kidney Fibrosis Drugs Product Offerings

7.4.5 InterMune Inc Recent Development

7.5 La Jolla Pharmaceutical Company

7.5.1 La Jolla Pharmaceutical Company Company Information

7.5.2 La Jolla Pharmaceutical Company Introduction and Business Overview

7.5.3 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.5.4 La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Offerings

7.5.5 La Jolla Pharmaceutical Company Recent Development

7.6 BioLine Rx

7.6.1 BioLine Rx Company Information

7.6.2 BioLine Rx Introduction and Business Overview

7.6.3 BioLine Rx Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.6.4 BioLine Rx Kidney Fibrosis Drugs Product Offerings

7.6.5 BioLine Rx Recent Development

7.7 F. Hoffman-La Roche

7.7.1 F. Hoffman-La Roche Company Information

7.7.2 F. Hoffman-La Roche Introduction and Business Overview

7.7.3 F. Hoffman-La Roche Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.7.4 F. Hoffman-La Roche Kidney Fibrosis Drugs Product Offerings

7.7.5 F. Hoffman-La Roche Recent Development

7.8 ProMetic Life-Sciences Inc

7.8.1 ProMetic Life-Sciences Inc Company Information

7.8.2 ProMetic Life-Sciences Inc Introduction and Business Overview

7.8.3 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.8.4 ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Offerings

7.8.5 ProMetic Life-Sciences Inc Recent Development

7.9 Genzyme Corporation

7.9.1 Genzyme Corporation Company Information

7.9.2 Genzyme Corporation Introduction and Business Overview

7.9.3 Genzyme Corporation Kidney Fibrosis Drugs Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Genzyme Corporation Kidney Fibrosis Drugs Product Offerings

7.9.5 Genzyme Corporation Recent Development

8 Industry Chain Analysis

8.1 Kidney Fibrosis Drugs Industrial Chain

8.2 Kidney Fibrosis Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Kidney Fibrosis Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Kidney Fibrosis Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Merck and Co.

Galectin Therapeutics

Pfizer Inc

InterMune

La Jolla Pharmaceutical Company

F. Hoffman-La Roche

ProMetic Life Sciences Inc

BioLine Rx

Genzyme Corporation

List of Tables

Table 1. Kidney Fibrosis Drugs Market Trends

Table 2. Kidney Fibrosis Drugs Market Drivers & Opportunity

Table 3. Kidney Fibrosis Drugs Market Challenges

Table 4. Kidney Fibrosis Drugs Market Restraints

Table 5. Global Kidney Fibrosis Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Kidney Fibrosis Drugs Revenue Market Share by Company (2019-2024)

Table 7. Global Kidney Fibrosis Drugs Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Kidney Fibrosis Drugs Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Kidney Fibrosis Drugs Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Kidney Fibrosis Drugs Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Kidney Fibrosis Drugs Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Kidney Fibrosis Drugs

Table 13. Global Kidney Fibrosis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Drugs as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Kidney Fibrosis Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Kidney Fibrosis Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Kidney Fibrosis Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Kidney Fibrosis Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Kidney Fibrosis Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Kidney Fibrosis Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Kidney Fibrosis Drugs Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Kidney Fibrosis Drugs Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Kidney Fibrosis Drugs Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Kidney Fibrosis Drugs Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Kidney Fibrosis Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Kidney Fibrosis Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Kidney Fibrosis Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Kidney Fibrosis Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Kidney Fibrosis Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Kidney Fibrosis Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Kidney Fibrosis Drugs Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Kidney Fibrosis Drugs Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Kidney Fibrosis Drugs Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Kidney Fibrosis Drugs Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Kidney Fibrosis Drugs Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Kidney Fibrosis Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Kidney Fibrosis Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Kidney Fibrosis Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Kidney Fibrosis Drugs Sales Value by Region (2019-2024) & (%)

Table 44. Global Kidney Fibrosis Drugs Sales Value by Region (2025-2030) & (%)

Table 45. Global Kidney Fibrosis Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Kidney Fibrosis Drugs Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Kidney Fibrosis Drugs Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Kidney Fibrosis Drugs Sales Volume by Region (2019-2024) & (%)

Table 49. Global Kidney Fibrosis Drugs Sales Volume by Region (2025-2030) & (%)

Table 50. Global Kidney Fibrosis Drugs Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Kidney Fibrosis Drugs Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Kidney Fibrosis Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Kidney Fibrosis Drugs Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Kidney Fibrosis Drugs Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Kidney Fibrosis Drugs Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Kidney Fibrosis Drugs Sales Volume, (2025-2030) & (K Units)

Table 57. Merck and Co Company Information

Table 58. Merck and Co Introduction and Business Overview

Table 59. Merck and Co Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Merck and Co Kidney Fibrosis Drugs Product Offerings

Table 61. Merck and Co Recent Development

Table 62. Galectin Therapeutics Company Information

Table 63. Galectin Therapeutics Introduction and Business Overview

Table 64. Galectin Therapeutics Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Galectin Therapeutics Kidney Fibrosis Drugs Product Offerings

Table 66. Galectin Therapeutics Recent Development

Table 67. Pfizer Inc Company Information

Table 68. Pfizer Inc Introduction and Business Overview

Table 69. Pfizer Inc Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Pfizer Inc Kidney Fibrosis Drugs Product Offerings

Table 71. Pfizer Inc Recent Development

Table 72. InterMune Inc Company Information

Table 73. InterMune Inc Introduction and Business Overview

Table 74. InterMune Inc Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. InterMune Inc Kidney Fibrosis Drugs Product Offerings

Table 76. InterMune Inc Recent Development

Table 77. La Jolla Pharmaceutical Company Company Information

Table 78. La Jolla Pharmaceutical Company Introduction and Business Overview

Table 79. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. La Jolla Pharmaceutical Company Kidney Fibrosis Drugs Product Offerings

Table 81. La Jolla Pharmaceutical Company Recent Development

Table 82. BioLine Rx Company Information

Table 83. BioLine Rx Introduction and Business Overview

Table 84. BioLine Rx Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. BioLine Rx Kidney Fibrosis Drugs Product Offerings

Table 86. BioLine Rx Recent Development

Table 87. F. Hoffman-La Roche Company Information

Table 88. F. Hoffman-La Roche Introduction and Business Overview

Table 89. F. Hoffman-La Roche Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. F. Hoffman-La Roche Kidney Fibrosis Drugs Product Offerings

Table 91. F. Hoffman-La Roche Recent Development

Table 92. ProMetic Life-Sciences Inc Company Information

Table 93. ProMetic Life-Sciences Inc Introduction and Business Overview

Table 94. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. ProMetic Life-Sciences Inc Kidney Fibrosis Drugs Product Offerings

Table 96. ProMetic Life-Sciences Inc Recent Development

Table 97. Genzyme Corporation Company Information

Table 98. Genzyme Corporation Introduction and Business Overview

Table 99. Genzyme Corporation Kidney Fibrosis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Genzyme Corporation Kidney Fibrosis Drugs Product Offerings

Table 101. Genzyme Corporation Recent Development

Table 102. Key Raw Materials Lists

Table 103. Raw Materials Key Suppliers Lists

Table 104. Kidney Fibrosis Drugs Downstream Customers

Table 105. Kidney Fibrosis Drugs Distributors List

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

List of Figures

Figure 1. Kidney Fibrosis Drugs Product Picture

Figure 2. Global Kidney Fibrosis Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Kidney Fibrosis Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Kidney Fibrosis Drugs Sales Volume (2019-2030) & (K Units)

Figure 5. Global Kidney Fibrosis Drugs Sales Price (2019-2030) & (US$/Unit)

Figure 6. Kidney Fibrosis Drugs Report Years Considered

Figure 7. Global Kidney Fibrosis Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Kidney Fibrosis Drugs Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Kidney Fibrosis Drugs Revenue in 2023

Figure 10. Kidney Fibrosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Angiotensin Converting Enzyme (ACE) Inhibitors Picture

Figure 12. Pirfenidone Picture

Figure 13. Renin Inhibitors Picture

Figure 14. Angiotensin II Receptor Blockers (ARBs) Picture

Figure 15. Vasopeptidase Inhibitors Picture

Figure 16. Global Kidney Fibrosis Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Kidney Fibrosis Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 18. Global Kidney Fibrosis Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 19. Global Kidney Fibrosis Drugs Sales Volume Market Share by Type, 2023 & 2030

Figure 20. Global Kidney Fibrosis Drugs Price by Type (2019-2030) & (US$/Unit)

Figure 21. Product Picture of Chronic Kidney Diseases

Figure 22. Product Picture of Kidney Cancer Treatment

Figure 23. Product Picture of Others

Figure 24. Global Kidney Fibrosis Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 25. Global Kidney Fibrosis Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 26. Global Kidney Fibrosis Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 27. Global Kidney Fibrosis Drugs Sales Volume Market Share by Application, 2023 & 2030

Figure 28. Global Kidney Fibrosis Drugs Price by Application (2019-2030) & (US$/Unit)

Figure 29. North America Kidney Fibrosis Drugs Sales Value (2019-2030) & (US$ Million)

Figure 30. North America Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

Figure 31. Europe Kidney Fibrosis Drugs Sales Value (2019-2030) & (US$ Million)

Figure 32. Europe Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

Figure 33. Asia Pacific Kidney Fibrosis Drugs Sales Value (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

Figure 35. South America Kidney Fibrosis Drugs Sales Value (2019-2030) & (US$ Million)

Figure 36. South America Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

Figure 37. Middle East & Africa Kidney Fibrosis Drugs Sales Value (2019-2030) & (US$ Million)

Figure 38. Middle East & Africa Kidney Fibrosis Drugs Sales Value by Country (%), 2023 VS 2030

Figure 39. Key Countries/Regions Kidney Fibrosis Drugs Sales Value (%), (2019-2030)

Figure 40. Key Countries/Regions Kidney Fibrosis Drugs Sales Volume (%), (2019-2030)

Figure 41. United States Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 42. United States Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 43. United States Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 44. Europe Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 45. Europe Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 46. Europe Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 47. China Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 48. China Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 49. China Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 50. Japan Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 51. Japan Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 52. Japan Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 53. South Korea Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 54. South Korea Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 55. South Korea Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 56. Southeast Asia Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 57. Southeast Asia Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 58. Southeast Asia Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 59. India Kidney Fibrosis Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 60. India Kidney Fibrosis Drugs Sales Value by Type (%), 2023 VS 2030

Figure 61. India Kidney Fibrosis Drugs Sales Value by Application (%), 2023 VS 2030

Figure 62. Kidney Fibrosis Drugs Industrial Chain

Figure 63. Kidney Fibrosis Drugs Manufacturing Cost Structure

Figure 64. Channels of Distribution (Direct Sales, and Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Renal Disease Treatment Market Research Report 2024

Global Chronic Kidney Disease Drugs Market Research Report 2025

Rare Kidney Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Idiopathic Pulmonary Fibrosis Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Complement Drug for Kidney Disease Market Research Report 2024

Polycystic Kidney Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kidney Cancer Diagnosis Market Research Report 2025

Acute Kidney Injury Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kidney Cancer Targeted Therapy Market Research Report 2025

Global Drugs for Retroperitoneal Fibrosis Market Research Report 2024

Global Polycystic Kidney Disease Treatment Market Research Report 2025

Global Renal Anemia Therapeutics Market Research Report 2025

Urinary Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Continuous Renal Replacement Therapy Market Research Report 2024

Pharmaceutical Retail Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Acquired Cystic Kidney Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Idiopathic Pulmonary Fibrosis Drug Market Research Report 2025

Urinary System Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Kidney Fibrosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions